ID: ALA4866833

Max Phase: Preclinical

Molecular Formula: C21H23ClN6O5S

Molecular Weight: 506.97

Molecule Type: Unknown

Associated Items:

Representations

Canonical SMILES:  NS(=O)(=O)OC[C@H]1C[C@@H](Nc2ncncc2C(=O)c2ccn(Cc3ccccc3Cl)n2)C[C@@H]1O

Standard InChI:  InChI=1S/C21H23ClN6O5S/c22-17-4-2-1-3-13(17)10-28-6-5-18(27-28)20(30)16-9-24-12-25-21(16)26-15-7-14(19(29)8-15)11-33-34(23,31)32/h1-6,9,12,14-15,19,29H,7-8,10-11H2,(H2,23,31,32)(H,24,25,26)/t14-,15-,19+/m1/s1

Standard InChI Key:  UKXNNPGADCVLBH-CLCXKQKWSA-N

Associated Targets(Human)

SUMO-activating enzyme 861 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

NEDD8 activating enzyme 447 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 506.97Molecular Weight (Monoisotopic): 506.1139AlogP: 1.38#Rotatable Bonds: 9
Polar Surface Area: 162.32Molecular Species: NEUTRALHBA: 10HBD: 3
#RO5 Violations: 1HBA (Lipinski): 11HBD (Lipinski): 4#RO5 Violations (Lipinski): 2
CX Acidic pKa: 11.40CX Basic pKa: 4.09CX LogP: 1.71CX LogD: 1.71
Aromatic Rings: 3Heavy Atoms: 34QED Weighted: 0.36Np Likeness Score: -1.06

References

1. Langston SP, Grossman S, England D, Afroze R, Bence N, Bowman D, Bump N, Chau R, Chuang BC, Claiborne C, Cohen L, Connolly K, Duffey M, Durvasula N, Freeze S, Gallery M, Galvin K, Gaulin J, Gershman R, Greenspan P, Grieves J, Guo J, Gulavita N, Hailu S, He X, Hoar K, Hu Y, Hu Z, Ito M, Kim MS, Lane SW, Lok D, Lublinsky A, Mallender W, McIntyre C, Minissale J, Mizutani H, Mizutani M, Molchinova N, Ono K, Patil A, Qian M, Riceberg J, Shindi V, Sintchak MD, Song K, Soucy T, Wang Y, Xu H, Yang X, Zawadzka A, Zhang J, Pulukuri SM..  (2021)  Discovery of TAK-981, a First-in-Class Inhibitor of SUMO-Activating Enzyme for the Treatment of Cancer.,  64  (5.0): [PMID:33631934] [10.1021/acs.jmedchem.0c01491]

Source